Is liraglutide actually inferior to newer GLP-1 drugs for weight loss?

What did @drmichaelrusso actually say?

Dr. Russo's core argument is straightforward: liraglutide (Saxenda/Victoza) is less effective for weight loss than semaglutide or tirzepatide, requires daily injections instead of weekly ones, and is generally not worth recommending unless it's the only insurance-covered option. He calls it a fallback, not a first choice.

He frames this in the context of GLP-1 shortages pushing people toward older medications. His exact words: "there are many many better options available than the results seen with lira glutide." He does give liraglutide credit as the right call when it's "the only one they're going to cover." That nuance matters and is worth acknowledging.

This is not a fringe take. It reflects a fairly standard clinical hierarchy among GLP-1 receptor agonists. But let's look at whether the evidence actually supports it.

Does the science back this up?

Yes, mostly. The weight loss data across these three drugs is not close, and Dr. Russo is on solid ground here. The SCALE trial (Davies et al., 2015, The Lancet) showed liraglutide 3.0 mg produced roughly 8% total body weight loss at one year. Compare that to the STEP 1 trial (Wilding et al., 2021, NEJM), where semaglutide 2.4 mg produced about 14.9% weight loss. Tirzepatide's SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) pushed that further, with up to 22.5% weight loss at the highest dose.

So the gap between liraglutide and its newer competitors is real and clinically meaningful, not just statistical noise. A difference of 6-14 percentage points in body weight is the kind of thing that changes cardiovascular risk profiles, not just pants sizes.

On dosing frequency: liraglutide is indeed a daily subcutaneous injection. Semaglutide and tirzepatide are weekly. That's not a minor lifestyle difference for most patients.

What did they get wrong (or right)?

Dr. Russo got the big picture right. The effectiveness hierarchy he describes matches the clinical trial data. He also avoided overclaiming, which is more than you can say for a lot of GLP-1 content on TikTok.

A few things worth flagging, though. He doesn't mention that liraglutide has a longer real-world safety record than semaglutide and tirzepatide. Liraglutide has been on the market since 2010 for type 2 diabetes and 2014 for obesity. Some clinicians and patients actually value that longer post-market surveillance window.

He also doesn't address the cardiovascular outcomes data. The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide reduced major cardiovascular events in people with type 2 diabetes. That's a meaningful outcome, and dismissing liraglutide without mentioning this gives an incomplete picture for a diabetic patient audience.

His framing of liraglutide as essentially a last resort is clinically defensible but oversimplified for a general audience that may not understand why a drug with real cardiovascular benefit gets ranked last on a TikTok.

What should you actually know?

If your goal is maximizing weight loss, the data supports starting with semaglutide or tirzepatide over liraglutide, assuming access and tolerability aren't obstacles. That's not controversial at this point.

But medication choice is not just about which drug wins a head-to-head weight loss trial. Factors like insurance formularies, individual GI tolerability, injection frequency preferences, and underlying conditions all shape what the right choice actually is for a specific person. Dr. Russo nods at this with his insurance comment, but a 90-second TikTok can't fully carry that nuance.

Liraglutide is not a bad drug. It's an older drug in a class where the newer entrants have been genuinely impressive. That's a different thing. If it's what's available to you, the clinical evidence still shows meaningful metabolic and cardiovascular benefit. Anyone telling you liraglutide is useless is overselling the competition.

• Talk to a licensed provider before switching or starting any GLP-1 medication.
• Insurance coverage and prior authorization requirements vary significantly by plan and diagnosis code.
• Compounded versions of these drugs are not equivalent to FDA-approved brand-name products.